Specialized proresolving mediators (SPMs) are endogenous lipid metabolites of long‐chain polyunsaturated fatty acids that are involved in promoting the resolution of inflammation. Many disease conditions characterized by excessive inflammation have impaired or altered SPM biosynthesis, which may lead to chronic, unresolved inflammation. Exogenous administration of SPMs in infectious conditions has been shown to be effective at improving infection clearance and survival in preclinical models. SPMs have also shown tremendous promise in the context of inflammatory lung conditions, such as acute respiratory distress syndrome and chronic obstructive pulmonary disease, mostly in preclinical settings. To date, SPMs have not been studied in the context of the novel Coronavirus, severe acute respiratory syndrome Coronavirus‐2 (SARS‐CoV‐2), however their preclinical efficacy in combatting infections and improving acute respiratory distress suggest they may be a valuable resource in the fight against Coronavirus disease‐19 (COVID‐19). Overall, while the research on SPMs is still evolving, they may offer a novel therapeutic option for inflammatory conditions.

专门的促分解介质（SPM）是长链多不饱和脂肪酸的内源性脂质代谢产物，参与促进炎症的消退。以过度炎症为特征的许多疾病状况已经损害或改变了SPM生物合成，这可能导致慢性，未解决的炎症。在临床前模型中，在感染性条件下外源给予SPM已显示可有效改善感染清除率和存活率。SPM在炎症性肺部疾病（例如急性呼吸窘迫综合征和慢性阻塞性肺疾病）的背景下也显示出巨大的希望，主要是在临床前环境中。迄今为止，尚未在新型冠状病毒，严重急性呼吸系统综合症冠状病毒2（SARS-CoV-2），然而，它们在抵抗感染和改善急性呼吸窘迫方面的临床前功效表明，它们可能是对抗冠状病毒19号（COVID-19）的宝贵资源。总体而言，尽管对SPM的研究仍在不断发展，但它们可能为炎症性疾病提供新颖的治疗选择。